Vigil Neuroscience (NASDAQ:VIGL) Earns Market Perform Rating from JMP Securities

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report)'s stock had its "market perform" rating restated by equities researchers at JMP Securities in a report issued on Thursday,Benzinga reports.

VIGL has been the topic of a number of other reports. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Wedbush cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and dropped their price objective for the stock from $13.00 to $8.00 in a report on Thursday, May 22nd. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, HC Wainwright dropped their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Nine analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of "Hold" and an average target price of $11.50.

Vigil Neuroscience Stock Down 0.1%

Shares of NASDAQ:VIGL traded down $0.01 on Thursday, reaching $7.89. 1,731,435 shares of the company's stock were exchanged, compared to its average volume of 641,272. The firm has a market capitalization of $368.01 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The business's 50-day moving average is $2.31 and its two-hundred day moving average is $2.31.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc grew its position in Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after buying an additional 293,461 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares in the last quarter. Barclays PLC grew its position in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares in the last quarter. Blair William & Co. IL bought a new position in Vigil Neuroscience in the 4th quarter valued at about $551,000. Finally, 683 Capital Management LLC grew its position in Vigil Neuroscience by 14.8% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock valued at $2,380,000 after buying an additional 180,420 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.